Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.
about
Multiple roles for nicotine in Parkinson's diseaseMammalian nicotinic acetylcholine receptors: from structure to functionA genetic basis for the variable effect of smoking/nicotine on Parkinson's disease.Smoking duration, intensity, and risk of Parkinson diseaseNicotine from cigarette smoking and diet and Parkinson disease: a review.Nicotine as a potential neuroprotective agent for Parkinson's disease.α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.Nicotine and Parkinson's disease: implications for therapy.Nicotinic receptors as CNS targets for Parkinson's diseaseChronic Nicotine Mitigates Aberrant Inhibitory Motor Learning Induced by Motor Experience under Dopamine Deficiency.Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's diseaseNicotine and inflammatory neurological disorders.Two Novel Sets of Genes Essential for Nicotine Degradation by Sphingomonas melonis TY.Characterization of a Novel Nicotine Degradation Gene Cluster ndp in Sphingomonas melonis TY and Its Evolutionary Analysis.Targeting nicotinic receptors for Parkinson's disease therapy.Can nicotine be used medicinally in Parkinson's disease?Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsPreclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.Current and experimental treatments of Parkinson disease: A guide for neuroscientists.Therapeutic potential of α7 nicotinic receptor agonists to regulate neuroinflammation in neurodegenerative diseases.Chronic high dose transdermal nicotine in Parkinson's disease: an open trial.Formulation and statistical optimization of novel double-incorporated PLA-PLGA microparticles within an alginate-pectinate platform for the delivery of nicotine.Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.Survival of Parkinson's disease patients in a large prospective cohort of male health professionals.
P2860
Q22252514-D98550FF-1EDB-4FC7-8DA6-4B70FA56A3BDQ24647069-035A1B9A-BB5E-4B69-B794-F09E25FE6762Q30531483-D4B42058-64A9-4F54-ACCB-3D716765E3ADQ33720760-28250996-9CC2-4F75-90CE-AC565586D270Q33862534-4CAE2B7D-5732-4F6E-B982-3E5DA788EED1Q34281003-30EAFC21-F5DD-48B2-B7AF-B1BE1C048A47Q35264378-EE6CA898-9A60-4379-8A96-8AE1105B2553Q35601652-110BBFB0-7B0B-4FD5-9B89-AD74442B3F17Q36882136-EAF3DF78-CDA3-42AB-AF5B-43FD4E209B08Q36889608-2AB1F186-F623-406A-9A85-583B23ED71D3Q36989832-98964715-76FB-4605-8C9D-D3E064BC6DFBQ37193201-ECBA9C77-EBFB-46F9-AF8B-CC85DDCCC117Q37209730-264C0217-AEB3-4E62-B458-11B1E2E2B421Q37485944-E5588B9F-8D83-45A4-BE90-AF03FA1697EDQ37588614-BCF170D0-DE64-4764-9EA9-EF906E4DC876Q37689553-40262DE0-D926-4F0A-B52A-114270198139Q37916643-7392598B-7C0C-441E-8C86-DD5D9E2A6B09Q37960523-54C5E16C-3A64-4FE4-834B-2FCBE5037CC3Q38156760-B03371A8-BF2E-4F69-9DBE-022A82B16CDFQ38629277-BE31C8F2-3A1E-4962-8F82-4F168D712C26Q38941557-EE6E0E46-199F-4DAE-ACAC-C3693DD553BCQ42962276-E98B5A9D-ADB2-4798-B07C-CC5358148F9EQ46946186-BBB4DF6F-418C-436F-8C1C-73F79538CB2FQ48509430-00461A67-B059-4F02-AD00-B4F031ADB3C6Q48642615-7BBEAB47-4446-4203-B9AB-575A6FB0B6E3Q51944364-F30AF4CC-7D0C-4D15-81F9-55B883E76207
P2860
Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Lack of efficacy of a nicotine ...... ficits in Parkinson's disease.
@en
Lack of efficacy of a nicotine ...... ficits in Parkinson's disease.
@nl
type
label
Lack of efficacy of a nicotine ...... ficits in Parkinson's disease.
@en
Lack of efficacy of a nicotine ...... ficits in Parkinson's disease.
@nl
prefLabel
Lack of efficacy of a nicotine ...... ficits in Parkinson's disease.
@en
Lack of efficacy of a nicotine ...... ficits in Parkinson's disease.
@nl
P2093
P1476
Lack of efficacy of a nicotine ...... ficits in Parkinson's disease.
@en
P2093
Anne Beuter
Hélène Masson
Marc-André Bédard
Pierre Blanchet
Simon Lemay
Sylvain Chouinard
Valérie Soland
P356
10.1016/S0278-5846(03)00172-6
P577
2004-01-01T00:00:00Z